Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2026 10:00 ET | Source: Baylor Genetics

Baylor Genetics Connects with Genetic Counselors to Advance Answers in Rare and Undiagnosed Disease

HOUSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it...
March 23, 2026 08:30 ET | Source: CDT Equity Inc.

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
March 12, 2026 02:00 ET | Source: Pharming Group N.V.

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
March 10, 2026 10:00 ET | Source: Baylor Genetics

Baylor Genetics Enhances Whole Genome Sequencing Test with Optical Genome Mapping and Long‑Read Sequencing as Supplemental Technologies

HOUSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, today announced enhancements to...
March 06, 2026 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
March 05, 2026 07:30 ET | Source: Biogen Inc.

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA,...
March 04, 2026 17:05 ET | Source: Biogen Inc.

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support...
March 04, 2026 10:00 ET | Source: Baylor Genetics

Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting

HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, will showcase its...
March 02, 2026 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates

PYRUKYND (mitapivat) approved for adults with thalassemia in the United Arab Emirates
February 26, 2026 12:50 ET | Source: Allsup

Allsup Shares Key SSDI Eligibility Considerations For Rare Disorders

Belleville, Illinois, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...